Dana-Farber Cancer Institute (DFCI), Massachusetts General Hospital is a clinical research site located in Boston, Massachusetts, United States 02114.
Crixeo Health Trust Score: 58/100 (POOR). This profile has not yet been claimed by the site owner.
Dana-Farber Cancer Institute (DFCI), Massachusetts General Hospital has participated in 1 clinical trials.
Therapeutic areas: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Burkitt Lymphoma.
Sponsors: Medical College of Wisconsin.
Trust Score: 58/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
Dana-Farber Cancer Institute (DFCI), Massachusetts General Hospital has a Crixeo Trust Score of 58/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Dana-Farber Cancer Institute (DFCI), Massachusetts General Hospital has 1 clinical trials on record. Their work covers Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Burkitt Lymphoma.
Dana-Farber Cancer Institute (DFCI), Massachusetts General Hospital has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.